ePrints

Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma

Lookup NU author(s): Monique Zangarini, Philip Berry, Julieann Sludden, Professor Gareth Veal

Downloads

• Accepted version [.pdf]

Licence

This is the authors' accepted manuscript of an article that has been published in its final definitive form by Future Medicine Ltd., 2017.

For re-use rights please refer to the publisher's terms and conditions.

Abstract

© 2017 Future Science Ltd. Aim: SRA737 is an orally active small-molecule inhibitor of checkpoint kinase 1 being investigated in an oncology setting. A HPLC-MS/MS method for quantifying plasma concentrations of SRA737 was validated. Methods & results: Sample preparation involved protein precipitation with acetonitrile following addition of 13C15N-deuterated SRA737 as internal standard. A rapid and selective method was fully validated across a range of 5-20,000 ng/ml, exhibiting good sensitivity, overall precision (expressed as coefficient of variation) ≤8.0% and accuracy 96-102%. Consistently high recovery was observed, with no matrix effect and a lower limit of quantitation of 5 ng/ml. Conclusion: A novel method for analyzing SRA737 in human plasma has been validated and is now being utilized for quantification of SRA737 in a Phase I trial.

Publication metadata

Author(s): Zangarini M, Berry P, Sludden J, Raynaud FI, Banerji U, Jones P, Edwards D, Veal GJ

Publication type: Article

Publication status: Published

Journal: Bioanalysis

Year: 2017

Volume: 9

Issue: 13

Pages: 1001-1010

Print publication date: 01/07/2017

Online publication date: 10/07/2017

Acceptance date: 02/04/2016

Date deposited: 21/09/2017

ISSN (print): 1757-6180

ISSN (electronic): 1757-6199

Publisher: Future Medicine Ltd.

URL: https://doi.org/10.4155/bio-2017-0043

DOI: 10.4155/bio-2017-0043

Altmetrics

Share